… non-small-cell lung cancer (NSCLC) patients, but there is a lack of specific evidence to guide
treatment; … Most patients with non-small-cell lung cancer (NSCLC) are elderly but evidence …

… Collectively, osimertinib would be a more competitive first-line treatment for advanced
non-small cell lung cancer patients beyond the first-generation EGFR-TKIs and further OS data of …

… related to the treatment of patients with non–small-cell lung cancer (NSCLC)… therapy in
patients with completely resected stage I-IIIA NSCLC? Lung cancer is the leading cause of cancer …

… The search was performed with combinations of the following search terms: chemotherapy,
treatment, elderly, and non–small-cell lung cancer. Only articles published in English …

… in pilot or phase II trials rarely show prolonged survival beyond 2 months when these
regimens are compared with standard treatments for patients with advanced-stage non–small-cell …

… In the last 10 years, the introduction of immune-checkpoint inhibitors (ICI) into the treatment
of non–small cell lung cancer (NSCLC) has transformed the therapeutic landscape in this …

… Lung cancer remains the leading cause of cancer-related … of these patients have non-small
cell lung cancer (NSCLC), … resection remains the standard of care in fit patients. Ongoing …

… of cancer immunology also impacted lung cancer therapy. Immune checkpoint inhibitors are
now a routine in most lung cancer cases… of modern-day management of lung cancer, with an …

… new cases of lung cancer diagnosed and roughly 158,000 deaths from lung cancer. The …
who receive a diagnosis of lung cancer will have non-small cell lung cancer (NSCLC). It is …

… trial of cisplatin and vindesine versus supportive care only in advanced nonsmall cell lung
cancer. Br J … for patients with extensive nonsmall cell lung cancer. Cancer 67:2443-2447, 1991 …